1. |
Gao Y, Hu N, Han X, et al.Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China.BMC cancer, 2009, 9:269.
|
2. |
Innocenti F, Undevia SD, Iyer L, et al.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.J Clin Oncol, 2004, 22 (8):1382-1388.
|
3. |
Bhasker CR, McKinnon W, Stone A, et al.Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268:ethnic diversity of alleles and potential clinical significance.Pharmacogenetics, 2000, 10 (8):679-685.
|
4. |
Hecht JR.Gastrointestinal toxicity or irinotecan.Oncology (Williston Park), 1998, 12 (8 Suppl 6):72-78.
|
5. |
Mackenzie PI, Bock KW, Burchell B, et al.Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.Pharmacogenet Genomics, 2005, 15 (10):677-685.
|
6. |
Iyer L, Janisch L, Das S, et al.UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11).Proc Am Soc Clin Oncol, 2001, 19:178A.
|
7. |
Rosati G, Cordio S.Single-agent irinotecan as second-lined weekly chemotherapy in elderly patients with advanced colorectal cancer.Tumori, 2006, 92 (4):290-294.
|
8. |
Cote JF, Kirzin S, Kramar A, et al.UGT1A1 polymorphism can predict hematologic toxicity in patients treated with Irinotecan.Clin Cancer Res, 2007, 13:3269-3275.
|
9. |
王岩, 徐建明, 沈琳, 等.中国人尿苷二磷酸葡糖苷酸转移酶1A基因多态性与伊立替康毒性的相关性.中华肿瘤杂志, 2007, 29 (12):913-916.
|
10. |
Jada SR, Lim R, Wong CI, et al.Role of UGT1A1* 6, UGT1A1* 28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.Cancer Sci, 2007, 98 (9):1461-1467.
|
11. |
Rhodes KE, Zhang W, Yang DY, et al.Abcb1, UGT1A1 and oatp-c polymorphisms predict Irinotecan (CPT-11) toxicity.J Clin Oncol, 2006, 24 (18 suppl):3074.
|
12. |
Desai AA, Innocenti F, Ratain MJ.Pharmacogenomics:road to anti-cancer therapeutics nirvana? Ncogene, 2003, 22 (42):6621-6628.
|
13. |
Han JY, Lim HS, Shin ES, et al.Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in non-small cell lung cancer patients treated with irinotecan and cisplatin.J Clin Oncol, 2006, 24 (15):2237-2244.
|
14. |
Araki K, Fujita K, Ando Y, et al.A pharmacogenetic study of irinotecan:genetic polymorphisms in the coding region of UGT1A1 gene and SN-38 glucuronidation in the body.J Clin Oncol, 2006, 24 (18 suppl):13078.
|
15. |
Han J, Lee S, Lee D, et al.Pharmacogenetic prediction for tumor response, toxicity, and survival of NSCLC patients treated with irinotecan and cisplatin chemotherapy.J Clin Oncol, 2007, 25 (18suppl):3581.
|
16. |
Isobe H, Yamamoto N, Kunikane H, et al.A phase Ⅰ/Ⅱ, pharmacokinetic (PK) and pharmacogenomic (PG) study of weekly irinotecan (CPT-11) therapy for elderly patients with advanced non-small cell lung cancer.J Clin Oncol, 2007, 25 (18suppl):2539.
|
17. |
Premawardhena A, Fisher CA, Liu YT, et al.The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1):hematologic and evolutionary implications.Blood Cells Mol Dis, 2003, 31 (1):98-101.
|
18. |
Yong WP, Innocenti F, Ratain MJ.The role of pharmacogenetics in cancer therapeutics.Br J Clin Pharmacol, 2006, 62 (1):35-46.
|
19. |
Innocenti F, Undevia SD, Iyer L, et al.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.J Clin Oncol, 2004, 22 (8):1382-1388.
|
20. |
Schulz C, Heinemann V, Schalhorn A, et al.UGT1A1 gene polymorphism:Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.World J Gastroenterol, 2009, 15 (40):5058-5066.
|